Pulmonx Corporation (LUNG) AI Stock Analysis

Pulmonx Corporation is a medical technology company that provides minimally invasive devices for chronic obstructive pulmonary diseases. Its flagship offering is the Zephyr Endobronchial Valve, designed to treat hyperinflation in adults with severe emphysema through bronchoscopic intervention. The company also offers the Chartis Pulmonary Assessment System, which uses a balloon catheter and console with sensors to evaluate collateral ventilation. Additionally, its StratX Lung Analysis Platform delivers cloud-based quantitative computed tomography analysis to evaluate emphysema severity and lobar volume. Headquartered in Redwood City, California, Pulmonx serves patients across the United States, Europe, the Middle East, Africa, and the Asia-Pacific.

Pulmonx increased its annual revenue from $48.4M in FY2021 to $90.5M in FY2025, representing a 5-year revenue CAGR of 22.6%. Annual revenue growth moderated from 47.9% in FY2021 and 28.0% in FY2023 to 8.0% in FY2025. Gross margins remained stable between 73.6% in FY2021 and 74.2% in FY2025. Operating margin improved from -97.7% in FY2021 to -59.3% in FY2025, while net losses narrowed slightly from -$48.7M in FY2021 to -$54.0M in FY2025 after peaking at -$60.8M in FY2023. For the latest quarter ended June 30, 2026, quarterly revenue growth declined 4.6% year-over-year, and trailing twelve-month revenue was $87.4M with an operating margin of -39.8%.

As of June 30, 2026, Pulmonx held $55.8M in cash and short-term investments alongside $56.2M in total debt, resulting in net debt of $368,000. Shareholders' equity was $39.2M against total assets of $114.7M. The company maintains a current ratio of 4.32 and a debt-to-equity ratio of 1.43. Free cash flow was -$32.9M in FY2025, with capital expenditures of $452,000. Over the past 5 years, Pulmonx expanded its share count by 15.1%.

At a last close of $1.78 on October 16, 2026, Pulmonx had a market cap of $75.2M and an enterprise value of $86.9M. The stock trades at a price-to-sales multiple of 0.9x and an EV-to-revenue multiple of 1.0x, compared to a price-to-sales median of 4.1x for its US-listed Healthcare peers. Its forward P/E of 28.3x exceeds the peer median of 17.3x. Over the past 1 year, LUNG generated a return of 13.4%, trailing the S&P 500 return of 16.8%. Over 5 years, the stock is down 95.5%, whereas the S&P 500 gained 83.0%.

Wall Street analysts assign Pulmonx 3 Strong Buy and 2 Hold ratings, with no Buy, Sell, or Strong Sell recommendations. The mean price target is $3.40, representing an upside of 91.0% from the last close of $1.78. For the current fiscal year ending December 31, 2026, analysts estimate an EPS of -$1.04 on revenue of $90.5M. For the next fiscal year, 5 analysts expect revenue of $98.3M and EPS of -$0.94. The company beat EPS estimates in 3 of the last 4 quarters and is scheduled to report earnings next on October 27, 2026.

This page is an AI-written research summary of Pulmonx Corporation (LUNG). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: LUNG income statement, LUNG balance sheet, LUNG key metrics, LUNG analyst forecast, LUNG chart. See the LUNG stock overview for the latest quote and news.